<img src="https://ml.globenewswire.com/Resource/Download/dec0fe5d-b262-4ca7-94e0-1fd3856d07a8?size=2" nborder="0" align="left" hspace="5" vspace="5" title="CVKD Logo 2025.png" alt="Cadrenal Therapeutics Inc."/>PONTE VEDRA, Fla., May 19, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions, will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Spring 2026 Investor Conference, taking place virtually on Thursday, May 28, 2026. Company Webcast The webcast presentation will take place at 9:30 a.m. ET on Thursday, May 28, 2026. The webcast can be accessed by visiting the conference home page at <a href="https://www.globenewswire.com/Tracker?data=wbpgOmJJ8ZYpGS2CyubmhSaomXT6fXPv16lPIC3WhUS1hySXhpJNcsmqcW8oEkWG1-CM95SzCdA1uD94-rqyr_WaJidAcuU78EhuwkGlmFgl1Ji5SX5dc-Yle5gEx4UhczA0uQsdb01nRen1dS1B_A==" rel="nofollow" target="_blank" title="">https://lythampartners.com/spring2026/</a> or directly at <a href="https://www.globenewswire.com/Tracker?data=wbpgOmJJ8ZYpGS2CyubmhQj__cdj1AW0kRjbn8XGw0i5dTrH7pmMoxVrWWZkbiOlBa1-gw_RAT2x1lBsgpydRdDsxVPvbmaCfxNIIifyG3H42U3Zw75p5bgXqrUOSXRK4Eil18fs7r4W0y6i0NblZw==" rel="nofollow" target="_blank" title="">https://app.webinar.net/DxpqArQk70e</a>. The webcast will also be available for replay following the event. 1x1 Meetings Management will be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners at <a href="https://www.globenewswire.com/Tracker?data=x8N7aGfObUaiYaKbTpf3uQTpPWRaARzRMLRzk-7pOu24-4G_MB8FENoQ-38ETaT3WBHRZ8BRXk3h13_uWi-39GfqQory0bXTFteZpX3l2Kk=" rel="nofollow" target="_blank" title="1x1@lythampartners.com">1x1@lythampartners.com</a> or register for the event at <a href="https://www.globenewswire.com/Tracker?data=wbpgOmJJ8ZYpGS2CyubmhSaomXT6fXPv16lPIC3WhUS1hySXhpJNcsmqcW8oEkWGA4hSqfoLLutCI1ekcjpq8BQFqw7BeCtr0BKWq9GhAOfYXktzVjV0cKzyzrsISHzGvTUDJsYpiNOM1uZf-74nMuZdvbD7Rs2ZWMXNKJ-Aois=" rel="nofollow" target="_blank" title="">https://lythampartners.com/spring2026invreg/</a>. About Cadrenal Therapeutics, Inc. Cadrenal Therapeutics, Inc. is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its lead program, CAD-1005, is a first-in-class 12-LOX inhibitor for the treatment of heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. CAD-1005 has received Orphan Drug and Fast Track designations from the U.S. Food and Drug Administration, as well as orphan drug status from the European Medicines Agency. Second-generation 12-LOX oral therapeutics are also in development for chronic indications. The Company’s broader pipeline includes tecarfarin, a late-stage oral vitamin K antagonist designed to prevent heart attacks, strokes, and deaths from blood clots in patients requiring chronic anticoagulation, including those with end-stage kidney disease and left ventricular assist devices, and frunexian, a parenteral Factor XIa inhibitor intended for use in acute hospital settings. For more information, visit <a href="https://www.globenewswire.com/Tracker?data=wbpgOmJJ8ZYpGS2CyubmhSUAkMrXt8mJ6n3cYLqOouKhb_NXDkvyY_PsUYmQW5H4D74G3FjpTsBvsZSBn_bjQy0eNveTNbFQ_ycrWHlXQq0=" rel="nofollow" target="_blank" title="">https://www.cadrenal.com/</a> and connect with the Company on <a href="https://www.globenewswire.com/Tracker?data=Uv6oJSeXkoQjUGy5XisaFYzimeAppsaGzhjNLAZJRxapswX4B_FjjFN_5rn-kScUQ1n7QOX5p4ILXmVGl4w5HDkfWGnh_L5UwEquoDtX6MwzHq6PLOtSP9-ftlLfMaAk" rel="nofollow" target="_blank" title="">LinkedIn</a>. For more information, please contact: Lytham Partners, LLC Robert Blum, Managing Partner 602-889-9700 <a href="https://www.globenewswire.com/Tracker?data=wTPcx2dOcR07R6t0yjFv6BFgLvMoreImoarXlhtlCgXRmXqtRTeKjFiI8xig_TQgYwdRvi05ARHfQOcN51nXyCTHDj3vNX2awVQMSvpOn3QvV0t30sD8zzY1a62S1FY-" rel="nofollow" target="_blank" title="">CVKD@lythampartners.com</a> <img alt="" src='https://ml.globenewswire.com/media/MmZiNjJiMDktZWUwOC00ZjYzLWFlMmMtZThkYzYwMzE2NGRlLTEyNzMzOTktMjAyNi0wNS0xOS1lbg==/tiny/Cadrenal-Therapeutics-Inc-.png' referrerpolicy='no-referrer-when-downgrade' />

GlobeNewswire Inc.

Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn